Depo-Provera Label Warning History: From Bone Density to Meningioma

Why label history matters

A prescription drug label is a living regulatory document. It describes approved uses, dosing, contraindications, warnings, adverse reactions, drug interactions and patient counseling based on the record FDA has reviewed at a particular time. Comparing dated versions can show when language changed. It cannot, by itself, prove what a manufacturer knew on every earlier date, whether state-law duties were breached, or whether different words would have changed an individual prescribing decision.

For Depo-Provera CI, the label history now sits at the center of public interest because meningioma language appeared after decades of U.S. use. The clean way to report that history is to cite the actual FDA PDFs and the agency's supplement approval letter. Screenshots without revision dates and manufacturer webpages that update in place are less useful when the question is exactly what the approved document said at an earlier point.

2010: the established boxed warning was bone mineral density

The October 2010 prescribing information displayed a boxed warning for loss of bone mineral density. It stated that women using Depo-Provera CI may lose significant bone mineral density, that loss is greater with increasing duration and may not be completely reversible, and that use beyond two years was not recommended unless other contraceptive methods were considered inadequate. The label identified 150 mg every three months by deep intramuscular injection for pregnancy prevention.

That historical label is useful because it prevents a common mistake: assuming meningioma was the product's only or original major warning. Bone health, thromboembolic contraindications and other precautions were already part of prescribing information. The 2010 PDF is explicitly historical and directs readers to current labeling. It should never be used as today's medical instructions, but it is primary evidence of the language approved at that revision date.

January 2024: immediately before the dedicated warning

The FDA-hosted January 2024 Depo-Provera CI label retained the boxed bone-density warning and extensive professional and patient information. It did not contain the dedicated Section 5.4 meningioma warning found in the later 2025 version. That absence is a document comparison, not a conclusion that no information about hormones and meningioma existed anywhere in medicine. It also does not tell us, without a fuller administrative record, every exchange between FDA and the application holder.

February 5, 2024 is another documented point: FDA's later approval letter says Pfizer submitted the prior-approval supplements for Depo-Provera CI and depo-subQ provera 104 on that date. FDA also recorded a November 1, 2024 action letter and a June 12, 2025 complete-response amendment. Those dates show regulatory review occurred over time. The public approval letter does not reproduce every underlying submission, so responsible history should avoid guessing about nonpublic content.

2025: FDA approves meningioma labeling

FDA's supplement approval letter states that it approved additions concerning meningioma risk to Warnings and Precautions, Patient Counseling Information and the corresponding patient information. The current label says meningioma cases have been reported following repeated administration of medroxyprogesterone acetate, primarily with long-term use. It directs clinicians to monitor patients for signs and symptoms and to discontinue Depo-Provera CI or depo-subQ provera 104 if a meningioma is diagnosed.

The patient-facing material also tells patients about the reported risk and to contact a healthcare professional if symptoms occur. That is meaningful safety communication. Yet the regulatory wording is careful: “cases have been reported” does not provide an incidence rate for all users or state that every reported case was caused by the drug. The label must be read alongside the studies, clinical context and product-specific instructions—not transformed into a universal prediction.

Regulatory change and litigation are connected but not identical

Plaintiffs in MDL 3140 allege that DMPA products can cause meningioma and that warnings were inadequate; defendants dispute liability. The JPML's transfer order merely identified those shared allegations as a reason for coordination. A later FDA warning may be relevant evidence in litigation, but its legal effect can depend on dates, product, federal regulatory history, state law and the specific theory asserted. The MDL court was still managing a federal-preemption motion as of June 2026.

For patients, the practical source is the newest FDA-approved label plus a clinician who knows their medical history. For legal status, the practical source is the court docket. For historical research, it is the dated label archive and approval correspondence. Keeping those roles separate produces a more accurate answer: meningioma language was newly approved in 2025, the longstanding bone-density boxed warning remained, and neither document alone resolves a pending civil case.

Reader questions

Frequently asked questions